Canni med investor presentation third qtr 2017

1. Third Quarter 2017
Leader in Canadian Medical Cannabis
and International First Mover

2. DISCLAIMER
GENERAL
This documentation is a presentation of general background information about the activities of CanniMed Therapeutics Inc. (the “Company”, “CMED”, “us” or “we”). The information contained in this presentation is derived solely from otherwise
publicly available information concerning CMED and does not purport to be all-inclusive or to contain all the information that an investor may desire to have in evaluating whether or not to make an investment in CMED.
This presentation does not constitute or form part of any offer or invitation for the sale or purchase of securities or any of the assets, business or undertaking described herein nor shall it or any part of it form the basis of or be relied on in
connection with, or act as any inducement to enter into, any contract or commitment whatsoever. Recipients of this presentation who are considering acquiring securities of CMED are reminded that any such purchase or subscription must not be
made on the basis of the information contained in this presentation but are referred to the continuous disclosure documents of CMED filed on SEDAR at www.sedar.com. The contents of this presentation are not to be construed as legal, financial or
tax advice. Each prospective investor should contact his, her or its own legal adviser, independent financial adviser or tax adviser for legal, financial or tax advice.
No representation or warranty, express or implied, is made or given by or on behalf of CMED or any of its affiliates or subsidiary undertakings or any of the directors, officers or employees of any such entities as to the accuracy, completeness or
fairness of the information or opinions contained in this presentation and no responsibility or liability is accepted by any person for such information or opinions. In furnishing this presentation, CMED does not undertake or agree to any obligation to
provide the attendees with access to any additional information or to update this presentation or to correct any inaccuracies in, or omissions from, this presentation that may become apparent. No person has been authorised to give any
information or make any representations other than those contained in this presentation and, if given and/or made, such information or representations must not be relied upon as having been so authorised. The information and opinions contained
in this presentation are provided as at the date of this presentation.
In this presentation, all amounts are in Canadian dollars, unless otherwise indicated. Any graphs, tables or other information in this presentation demonstrating the historical performance of CMED or any other entity contained in this presentation
are intended only to illustrate past performance of such entities and are not necessarily indicative of future performance of CMED or such entities.
This presentation is being supplied to you solely for your information and may not be reproduced, further distributed or published in whole or in part by any other person. Distribution of this presentation may be restricted or prohibited by law.
Recipients are required to inform themselves of, and comply with, all such restrictions or prohibitions and CMED does not accept liability to any person in relation thereto.
FORWARD-LOOKING INFORMATION
This presentation contains “forward-looking information” within the meaning of applicable securities laws in Canada. Forward-looking information may relate to our future outlook and anticipated events or results and may include information
regarding our financial position, business strategy, growth strategies, budgets, operations, financial results, taxes, dividend policy, plans and objectives. Particularly, information regarding our expectations of future results, performance,
achievements, prospects or opportunities or the markets in which we operates is forward-looking information. In some cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “targets”,
“expects” or “does not expect”, “an opportunity exists”, “outlook”, “prospects”, “strategy”, “intends”, “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will”, “will
be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-
looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events or circumstances.
Forward-looking information contained in this presentation and other forward-looking information are based on our opinions, estimates and assumptions in light of our experience and perception of historical trends, current conditions and expected
future developments, as well as other factors that we currently believe are appropriate and reasonable in the circumstances. Despite a careful process to prepare and review the forward-looking information, there can be no assurance that the
underlying opinions, estimates and assumptions will prove to be correct.
Although we have attempted to identify important risk factors that could cause actual results to differ materially from those contained in forward-looking information in this presentation, there may be other risk factors not presently known to us or
that we presently believe are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information in this presentation. There can be no assurance that such information will
prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information, which speaks only as of the date
made. The forward-looking information contained in this presentation represents our expectations as of the date of this presentation or the date indicated, regardless of the time of delivery of the presentation. However, we disclaim any intention
or obligation or undertaking to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required under applicable securities laws in Canada. All of the forward-looking
information contained in this presentation is expressly qualified by the foregoing cautionary statements.
NON-IFRS MEASURES AND INDUSTRY METRICS
This presentation makes reference to certain non-IFRS measures including “EBITDA” and “Adjusted EBITDA”, and to certain operating metrics in the industry. Non-IFRS measures including industry metrics do not have a standardized meaning
prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS measures by providing further
understanding of our results of operations from management’s perspective. Accordingly, these measures should not be considered in isolation nor as a substitute for analysis of our financial information reported under IFRS. Please refer to the
Prospectus and the Company’s most recently filed MD&A, available on www.sedar.com, for further details on these non-IFRS measures including industry metrics, including relevant definitions and reconciliations.
2

3. SUMMARY OVERVIEW
CanniMed Therapeutics Inc.
An international, biopharmaceutical company and a leader in the
Canadian cannabis industry with best-in-class pharmaceutical-grade
cannabis products and a first mover advantage in rapidly
developing international markets
3

4. Experienced LP with a 15 year history of growing medical cannabis
INVESTOR HIGHLIGHTS
Pharmaceutical-
Grade;
GMP-compliant;
investing in clinical
trials
The Canadian medical market is
hereand now with growing
acceptance; increasing evidence of
effectiveness; Baby Boomers are a
significant market opportunity
First mover advantage
and best positioned to
address the massive
international market
opportunity
Strong management
and board
with broad experience in
cannabis, medical biotechnology,
and pharmaceuticals
Significant Revenue,
EBITDA and Volume
Growth
4

5. Recent
Developments
Strong Q3 2017 results
KG SOLD
(+79% 9mo/9mo)
ADJUSTED EBITDA
(+$1.2MM 9mo/9mo)
REVENUE
(+80% Q3/Q3)
Entered into Canada’s first exclusive
pharmacy distribution agreement for
medical cannabis
Commenced Cannabis Oils Facility
expansion with support of the
Saskatchewan provincial government
Agreement with CTT Pharmaceutical
Holdings Inc. (“CTT”) to License its Orally
Dissolvable Thin Film Wafer
5
Completed first oils exports to Australia
and Cayman Islands

6. Current Growth Focus
NEW DISTRIBUTION
CHANNELS
Pharmacy initiatives
ADDING CAPACITY
Oils facility, enclosed plant
growing expansion,
greenhouse conversions to
cannabis production
PURSUING EXPORTS
Multiple countries
CanniMed provides pharmacist education,
obtains exclusive or preferred distribution
Cannabis Oils Facility Expansion - civil works
commenced September, process engineering
under way
Sub-lingual wafers – application to Health
Canada
Topical cream in development
5
Inbound approaches from countries in North
America, Europe, Africa and Australasia
NEW DOSAGE FORMS
New enclosed production building to add
6,000 kg annual capacity – design stage,
completion 2019
Greenhouse conversions to add 4,000 to 8,000
kg annual capacity – completion 2018

7. Pharmaceutical Cannabis
7
THE OPPORTUNITY IS SIGNIFICANT
Increased risk
of addiction, overdose
and mortality
A strong need
for alternative
methods for pain
management
Seeking pain relief and
maintaining an active
lifestyle and manage
end-of-life conditions
Legislative, political
environments are
more favorable
towards medical
cannabis globally
Commonly prescribed
opioids
Increasing
healthcare costs
Rapidly aging
population
Canada
is a leader

8. To Provide a Step-Change in Demand
8
(1) Pain Resource Centre, 2015: Pain in Canada Fact Sheet (2) Canadian Pain Society. (3) Direct costs. Pain Resource Centre, 2015: Pain in Canada Fact
Sheet. (4) The Canadian Pain Society, 2011: Call to Action: The Need for a National Pain Strategy for Canada. (5) Globe and Mail, October 2014
$2
$193
2015
2010
21.7
2015
2010
1 in 5 Canadian
adults suffer
from chronic
pain(2)
Chronic
pain costs
more than
$6 billion
annually(3)
Inadequate pain
assessment and
treatment is a
growing problem in
Canada(4)
Opioids are
prescribed for
chronic pain despite
little evidence of
long term efficacy(5)
With an aging
population, the
incidence of
chronic pain
increases(1)
29%
of the Canadian
population
16% of seniors use opioids(3)
New delivery mechanisms such
as cannabis oils and gelcaps are ideally suited:
• More traditional forms
• Easier to target symptoms/doses
• Avoid stigmas associated
with smoking
Baby Boomers

9. Opportunities are Exploding
9
International markets are opening quickly for
pharma-quality products9
Cayman Islands
First ever sale
of commercial
cannabis oils
Australia
First ever shipment of
commercial cannabis oil;
follow-up orders for
additional oil products
United States
GMP compliant production
facility with potential to
support over 50,000 kg of
capacity per annum
• In process of applying to
the DEA for a licence to
supply for research
purposes
European Union
LOI with Creso Pharma Ltd. to market
CMED medical cannabis brands
International Markets
Worldwide population of baby
boomers is over 1.1 billion
Worldwide baby boomer
population is over 1.1 billion
Europe
~ 121 million
baby boomers
U.S.
~ 74 million
baby boomers
Australia
~ 5 million
baby boomers

10. Product differentiation
will be key
…………………………………….
CMED best-in-class oils
Provide significant opportunity
– particularly in consumables
High margin
…………………………………….
New delivery mechanisms provide
opportunities for IP
…………………………….………
Pharmacy distribution will be a game
changer
……………………………………..
Only pathway
to international markets
✓ GMP Compliant
✓ Extensive quality
control
✓ Precision growing
and extraction
✓ No pesticides
CanniMed is focused on
producing high-quality
products that are best
positioned in any market
10
(1) GMP are standards and procedures that
pharmaceutical companies must adhere to in
manufacturing their products in North America;
part of quality assurance that ensures that drugs
are consistently produced and controlled to meet
quality standards
Medical
Recreational
Well Positioned for the near
and long term
CanniMed Therapeutics

11. Herbal
CANNIMED PRODUCT OFFERING
Pharmaceutical-quality and branding
promotes doctor confidence and supports
more effective prescription dosages
Identified by the
percentage of THC
and CBD they contain
Each product is designed
with specific benefits in mind
to address each patient’s
requirements
Purple 1·13
0.7% THC
13.0% CBD
Red 4·10
4.0% THC
10.0% CBD
Orange 9·9
9.0% THC
9.5% CBD
Yellow 12·0
12.5% THC
<0.5% CBD
Green 15·5
15.0% THC
5.0% CBD
Blue 17·1
17.0% THC
0.7% CBD
Indigo 22·1
22.0% THC
0.7% CBD
11

12. Oils
CANNIMED PRODUCT OFFERING
For patients reluctant to smoke herbal product
• Ideal for palliative care and hospitalized patients
• Significant sales acceleration since launching oils in January
For baby boomers looking for a safe, reliable way
to manage their chronic pain symptoms and
maintain an active lifestyle
CANNABIS OILS CAPSULES PRODUCTION RAMP H2 2017
Higher margin, value-added products with
global market appeal
Purple 1·20
0.7
20.0
60
THC mg/ml
CBD mg/ml
THC mg
TOTAL CBD mg1,200
Orange 10·10
9.8
9.9
588
TOTAL CBD mg594
THC mg/ml
CBD mg/ml
THC mg
Blue 18·0
18.3
0.2
1,098
12
THC mg/ml
CBD mg/ml
THC mg
TOTAL CBD mg
12

13. Saskatoon, Saskatchewan
13
GMP-COMPLIANT PRODUCTION FACILITIES
(1) Benefited from technologies and innovations developed over the course of
seven distinct facility builds.
Good Production
Practices (GPP)
Required under ACMPR
International
Organization for
Standardization (ISO)
GMP Standards
Only LP deemed by Health
Canada to be compliant
Required for pharmaceutical
production
GMP
Above ground facility on 100 acres,
currently using approximately 20 acres
30 X 1,000 plant bio-secure growth chambers
7,000 kg current enclosed capacity;
State-of-the-art, GMP-compliant
5 separate Level 7 security
compliant vaults
“Seventh Generation”
facility(1)
production process
MOST RIGOROUS
RIGOROUS
LEAST RIGOROUS
and 6,000 kg new enclosed capacity in 2018-19
Adding 4-8,000 kg greenhouse conversion 2018

14. • “CAPRI Trial”(1)
- First Phase II Health Canada approved clinical
trial using cannabis ($1 million invested)
- Randomized, double-blind, placebo controlled,
proof-of-concept Phase IIA clinical trial
- Seeks to examine the varying ratios of THC and
CBD in patients with osteoarthritis of the knee
• “Identifying the molecular mechanisms involved
in suppressing multiple sclerosis induced
neuropathic pain following cannabinoid treatment
in an animal model of multiple sclerosis”
• Pre-clinical study partnering with Dr. Michael
Namaka at the University of Manitoba.
• “CARE-E Trial” in patients with refractory pediatric
epilepsy, partnered with Dr. Richard Huntsman at
the University of Saskatchewan.
• “PICATE Trial” in patients with Tourette’s
syndrome, partnered with Dr. Paul Sandor at
Toronto Western Hospital.
Investing in Clinical Trials
(1) Cannabinoid Profile Investigation of Vaporized Cannabis in Patients with Osteoarthritis of the Knee14

15. 18,512
658
109
1,177
416
Growing Momentum
15
REVENUE AND GROWTH
(1) Includes both dried herbal and oils
Total Dried Equivalents
(KG)(1)
Oil Equivalent
(KG)
Q3 % of Revenue
36% 57%
9 mo 2016 9 mo 2017
15
July 2016
Active Patients Physicians
7,631
4,222
2,863
July 2017

16. Historical Financials
16
REVENUE AND GROWTH
(1) LTM financial results include 9 months ended July 31, 2017;
Launching oils in 2016 has accelerated
growth and expanded opportunities for new
customers
Introduction of pharmaceutical-grade
capsules anticipated to accelerate growth in
Canada and internationally
Adj. EBITDA 2017
$(0.1M), 9 mo 2017
Aggressively expanding
infrastructure to meet
accelerating market demand
Revenue ($M)(1) Gross Margins ($M)(1)
2015
98% Margin
2016
84% Margin
LTM
63% Margin
2016 Q3 2017 Q3
$5.8 $5.7
$9.8
$8.2
$15.0
$9.5
$2.7
$2.1
$4.8
$2.6
Experiencing
Rapid Sales
Growth
40% of total kg sold, 9
mo 2017
Cannabis Oils

17. Capitalization
REVENUE AND GROWTH
OCTOBER 31, 2016
FISCAL YEAR-END ($M)
JULY 31, 2017
END Q3 ($M)
CASH 2.0 54.2
TOTAL CURRENT ASSETS 14.7 67.1
CURRENT LIABILITIES 7.8 5.5
DEBT 36.3 14.0
SHAREHOLDERS EQUITY 10.6 90.8
CURRENT MARKET CAPITALIZATION (Sept
12/17)
$208.9
CURRENT ENTERPRISE VALUE $168.7
17
(1) As of close of September 12, 2017; 22,958,261 shares outstanding.

18. Strong Management Team and Board
18
KEY MANAGEMENT
President & CEO
Brent H. Zettl
• President of CanniMed since 1991
• Spearheaded the development activities of the
innovative underground growth chambers
• 2014 E&Y Entrepreneur of the Year for the Prairies
Business-to-Consumer category
CFO
John Knowles
• 30 years executive and boards, Canada and overseas
• Director of CanniMed for over eight years and past Chair of the
Board’s Audit and Finance Committee
• Former VP, CFO of Hudbay Minerals Inc., Executive VP of Aur
Resources Inc., and CEO of LiCo Energy Metals Inc.
VP, Marketing and Sales
Larry Holbrook
• Background includes Senior Research Scientist positions
with extensive and diverse agricultural biotechnology
experience in both government and industrial settings
• Over 20 years of experience in basic research and
applications to genetic modification of crop plants
• Author or co-author on 40 publications and books
VP, Regulatory Affairs and Information Technology
Gulwant Bajwa
• Previously with Health Canada as a Senior Program
Manager in former Bureau of Medical Cannabis and as a
Policy Analyst in the Intellectual Property and Technology
Transfer office of Health Canada
• Five years as Director of Operations at JDS Uniphase
Corporation
Howard Harkness
• Background includes Senior Research Scientist positions
with extensive and diverse agricultural biotechnology
experience in both government and industrial settings
• Over 20 years of experience in basic research and
applications to genetic modification of crop plants
Chief Science Officer
• Broad experience in investment, financial management, and
business valuations
• Former CFO of Mosaic Capital Corp. with investments across
multiple industries
• Former VP Investments in energy-focused private equity.
Allan Fowler
VP, Business Development and Investor Relations

19. Strong Management Team and Board
19
BOARD OF DIRECTORS
LL.B, B.A. (Chairman)
Donald Ching
Director, Golden Opportunities Fund;
Former President and CEO of SaskTel
Doug Banzet
CFO and Director, Golden
Opportunities Fund
B.B.A.
Rob Duguid
Partner, PFM Capital; VP, Prairie Ventures
Fund
Ph.D.
Marianne Greer
Independent Pharmacist Consultant
B.Sc.
Richard Hoyt
VP, Business Development,
Mallinckrodt PLC
B.Comm, C.P.A., C.A.
Dwayne L. Lashyn
VP, Quantico Capital Corp.
Ph.D., J.D.
Bruce F. Mackler
Consultant in FDA, USDA and EPA Regulatory
Processes
Ph.D.
Brandon J. Price
Executive VP, Nascent Biotech; Co-
founder, Biogenin
B.Comm, C.P.A., C.A.
John L. Knowles
CFO and Director, CanniMed
Therapeutics Inc.
Brent Zettl
President, CEO and Director, CanniMed
Therapeutics Inc.
B.S.AB.B.A.